Navigation Links
IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial

nd its drug development programs include whether the Company or any of its collaborators will be able to develop pharmaceutical products using the technologies of the Company, whether clinical trial results to date are predictive of results of any future clinical trials, risks associated with completing clinical trials of product candidates, risks involved in the regulatory approval process for the Company's product candidates, the possibility that clinical testing may reveal undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products; whether the cash resources of the Company will be sufficient to fund operations as planned; whether any steps taken by the Company to contain costs will in fact result in sufficient reduction in expenses; reliance on key employees, especially senior management; the risk that the Company may not secure or maintain relationships with collaborators, and the Company's dependence on intellectual property. These factors are more fully discussed in the Company's Annual Report on Form 10-Q filed with the SEC for the quarter ended March 31, 2007 and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

CONTACT: Bob De Vaere, Chief Financial Officer of IDM Pharma, Inc.,+1-949-470-6447; or Geoff Curtis of WeissComm Partners, +1-312-550-8138,, for IDM Pharma, Inc. gcurtis@weisscommpartners.com

Web site: http://www.idm-pharma.com/

Ticker Symbol: (NASDAQ-NMS:IDMI)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:5/4/2015)... 4, 2015   HeartWare International, Inc . (NASDAQ: ... support technologies that are revolutionizing the treatment of advanced heart ... , is scheduled to present at the Bank of America ... Vegas on Thursday, May 14, 2015, at 10:00 ... of the Company,s presentation at the conference will be available ...
(Date:5/4/2015)... 2015 MEI Pharma, Inc. (Nasdaq: ... clinical development of novel therapies for cancer, today ... the Company,s investigational drug candidate ME-344 in cancer ... with a tyrosine-kinase inhibitor (TKI). In addition, a ... potent inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) complex ...
(Date:5/4/2015)... 2015 Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technologies are used to develop, manufacture and ... bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... for quarter ending March 31, 2015 after market ... host a conference call that day at 5:00 ...
Breaking Medicine Technology:HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 2Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 3
... The University HealthSystem Consortium (UHC) today announced an agreement with Centurion Service ... services. The contract was effective on February 1, 2010 . , ... Centurion, the world,s largest medical auction house with ... assists UHC members in the setup and management of their surplus asset programs ...
... (NYSE: ABT ) will present at the 26th Annual Sanford Bernstein ... York City .  Miles D. White, chairman and chief executive officer, will make ... , , , ... presentation will be accessible through Abbott,s Investor Relations Web site at www.abbottinvestor.com ...
Cached Medicine Technology:University HealthSystem Consortium Selects Centurion Service Group for Equipment and Asset Liquidation Services 2
(Date:5/4/2015)... San Diego Fertility Center (SDFC) ... brand new, 13,700 square foot facility scheduled to open ... not only provide fertility treatment and services for the ... and educational events to a number of local and ... door to their current Carmel Valley/Del Mar location and ...
(Date:5/4/2015)... May 04, 2015 Dr. Benjamin Stong ... proudly offers the latest non-surgical double-chin eliminator. Dr. ... plastic surgeon in Atlanta to offer Kybella treatments ... be injected specifically under the chin, promising to safely ... Before Kybella, patients who sought immediate solutions for their ...
(Date:5/4/2015)... May 04, 2015 Unlike some camps, the Nike ... knowledge. The goal is to educate first and train second, ... This ensures that the young runners are building the knowledge base ... few of the topics covered include Effort Based Training, Running Heroes, ... used to be? This is not a camp where kids ...
(Date:5/4/2015)... Dr. Richard Champagne, DMD, MAGD is pleased to ... America’s Best Dentist Award, given by the National Consumer ... dentist is a reflection of his vast experience in ... for his patients. , Each year, the National Consumer ... field. These nominees are dentists who have exceptionally high ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Sylvia Hawthorn-Deppen shared ... hopes that it would remind others in similar situations that ... Recovery from Chronic Pain and Discovery of New Energy” (published ... a new audience via a renewed press campaign. , “I ... debilitating pain ,” Hawthorn-Deppen says. “As an adolescent I ...
Breaking Medicine News(10 mins):Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 3Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2Health News:Author launches new press campaign for 2012 book ‘Wheel’ 2
... Teens Still Feel Targeted By Tobacco Advertising and Find ... Kids across Delaware,will rally against tobacco on April 2 ... 13th annual Kick Butts Day, sponsored by the,Campaign for ... (for a list of local events, go to ...
... By Tobacco Advertising and Find It,Easy to Buy Cigarettes, ... against tobacco on April 2 as they join thousands ... Day, sponsored by the,Campaign for Tobacco-Free Kids. Hundreds of ... local events, go to, http://www.kickbuttsday.org/events )., This year, ...
... (OTC,Bulletin Board: BNLB) is pleased to announce that sales ... at the beginning of this year, have,exceeded the company,s ... 2008., Fusion,s 6+ Hour Energy Shot was first ... past November, where it was voted,"Best Tasting Shot". Fusion ...
... N.C., March 27 Marshall Erdman &,Associates ... company by,"Modern Healthcare,s" 2008 Construction & Design ... the healthcare industry; it,examines year-over-year sales, contracted ... in business and number of architects, engineers,and ...
... 27 Biotest Pharmaceuticals,Corporation, a leading developer ... announcement that a Hepatitis B Immune Globulin,Intravenous ... received,Orphan Drug designation by the U.S. Food ... hepatitis B recurrence following orthotopic liver,transplantation., ...
... major licensing deals like the one his company recently ... front of mind for rising Australian biotechnology star, Antisense ... when he meets with leading industry figures in the ... scientists chosen from a highly competitive field of candidates ...
Cached Medicine News:Health News:Delaware Kids 'Kick Butts' on April 2 2Health News:Delaware Kids 'Kick Butts' on April 2 3Health News:Georgia Kids 'Kick Butts' on April 2 2Health News:Georgia Kids 'Kick Butts' on April 2 3Health News:Bond Laboratories' First Quarter Fiscal 2008 Sales Exceeding Internal Projections 2Health News:'Modern Healthcare' Names Marshall Erdman Nation's Top Design-Build Company 2Health News:Biotest Pharmaceuticals Corporation Responds to Orphan Drug Act Announcement 2Health News:Antisense therapeutics scientist out to pull more big deals 2
Freedom of movement - plus full circle, maximum radiation protection. No other full circle radiation protection design approaches the level of comfort of the VestSkirt, which divides weight between t...
... Cryo System is the first in portability and performance. ... surgeons who need a flexible, portable system with the ... CTU attaches easily to an "E" size tank and ... cryo to where it is needed.,The CTU Travel Case ...
... an easy-to-use, workflow-based system designed to save you ... of the SleepWorks software and either the Connex ... systems can be used for a complete range ... full EEG recording - and have superior signal ...
... Merci Retrieval System is made up of ... Merci Microcatheter and the Merci Balloon Guide ... Once the location of the clot has ... Guide Catheter is inserted through a small ...
Medicine Products: